ABOUT THIS EPISODE
The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?
Guests:
- Tay Salimullah, Chief Access Commercial Officer at Novartis
- Jason Jones, Global Business Development Lead at Cellular Origins
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Invent: Life Sciences.
OTHER EPISODES IN THIS PODCAST
Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and product…
Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufactu…
Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry.
We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future …
Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.
With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this…
Disclaimer: The podcast and artwork embedded on this page are from TTP plc, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
